These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36213303)

  • 1. Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast].
    Drummond MF; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7487-7492. PubMed ID: 36213303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast].
    Sullivan SD; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7879-7884. PubMed ID: 36325498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast].
    Garrison LP; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8217-8224. PubMed ID: 36451799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value Insider Season 1 Episode 2: How to Measure Quality of Life and Utility? (QoL) [Podcast].
    Devlin NJ; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7773-7779. PubMed ID: 36263308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast].
    Kanavos PG; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8429-8435. PubMed ID: 36518234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Insider Season 1 Episode 4: How are Costs Measured, and How are CEAs Constructed and Used? (CEA) [Podcast].
    Rutten-van Mölken MPMH; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8055-8061. PubMed ID: 36389024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 10. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting (May 17-20, 2021 - Virtual Meeting).
    Kibble A
    Drugs Today (Barc); 2021 Aug; 57(8):519-525. PubMed ID: 34405209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.
    Nestler-Parr S; Korchagina D; Toumi M; Pashos CL; Blanchette C; Molsen E; Morel T; Simoens S; Kaló Z; Gatermann R; Redekop W
    Value Health; 2018 May; 21(5):493-500. PubMed ID: 29753344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report.
    Drummond MF; Augustovski F; Bhattacharyya D; Campbell J; Chaiyakanapruk N; Chen Y; Galindo-Suarez RM; Guerino J; Mejía A; Mujoomdar M; Ollendorf D; Ronquest N; Torbica A; Tsiao E; Watkins J; Yeung K;
    Value Health; 2022 Aug; 25(8):1257-1267. PubMed ID: 35931428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
    Gyldmark M; Lampe K; Ruof J; Pöhlmann J; Hebborn A; Kristensen FB
    Int J Technol Assess Health Care; 2018 Jan; 34(5):458-463. PubMed ID: 30334508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interview: Health technology assessment in Asia: an emerging trend.
    Yang BM
    J Comp Eff Res; 2012 May; 1(3):221-4. PubMed ID: 24237405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
    Wang T; McAuslane N; Liberti L; Gardarsdottir H; Goettsch W; Leufkens H
    Front Pharmacol; 2020; 11():594549. PubMed ID: 33390978
    [No Abstract]   [Full Text] [Related]  

  • 18. Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019.
    Inotai A; Németh B
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):379-381. PubMed ID: 31159614
    [No Abstract]   [Full Text] [Related]  

  • 19. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
    Mittermayer R; Huić M; Mestrović J
    Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.